BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

7691 related articles for article (PubMed ID: 20414921)

  • 21. Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies.
    Basu B; Biswas S; Wrigley J; Sirohi B; Corrie P
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1583-98. PubMed ID: 19895243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
    Egberts F; Kahler KC; Livingstone E; Hauschild A
    Onkologie; 2008 Jul; 31(7):398-403. PubMed ID: 18596389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogenetics of melanoma: basis for molecular diagnostics and therapy.
    Held L; Eigentler TK; Meier F; Held M; Röcken M; Garbe C; Bauer J
    J Dtsch Dermatol Ges; 2011 Jul; 9(7):510-6. PubMed ID: 21244632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging therapies for melanoma.
    Katipamula R; Markovic SN
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):553-60. PubMed ID: 18402522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New therapeutic targets in melanoma.
    Martí RM; Sorolla A; Yeramian A
    Actas Dermosifiliogr; 2012 Sep; 103(7):579-90. PubMed ID: 22261672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF kinase in melanoma development and progression.
    DeLuca AM; Srinivas A; Alani RM
    Expert Rev Mol Med; 2008 Feb; 10():e6. PubMed ID: 18279546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted molecular therapy in melanoma.
    Puzanov I; Flaherty KT
    Semin Cutan Med Surg; 2010 Sep; 29(3):196-201. PubMed ID: 21051014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF inhibitors and melanoma.
    Flaherty KT
    Cancer J; 2011; 17(6):505-11. PubMed ID: 22157295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular targets in melanoma from angiogenesis to apoptosis.
    Sosman JA; Puzanov I
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2376s-2383s. PubMed ID: 16609062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Kinase inhibitors for the therapy of malignant melanoma].
    Becker JC; Schrama D; Bröcker EB; Houben R
    J Dtsch Dermatol Ges; 2005 Oct; 3(10):762-7. PubMed ID: 16194153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel treatment strategies for malignant melanoma: a new beginning?
    Kasper B; D'Hondt V; Vereecken P; Awada A
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):16-22. PubMed ID: 17208006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is it good or bad to find a BRAF mutation?
    Flaherty KT
    J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
    [No Abstract]   [Full Text] [Related]  

  • 34. Management of metastatic melanoma.
    Tawbi HA; Kirkwood JM
    Semin Oncol; 2007 Dec; 34(6):532-45. PubMed ID: 18083377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting oncogenic drivers and the immune system in melanoma.
    McArthur GA; Ribas A
    J Clin Oncol; 2013 Feb; 31(4):499-506. PubMed ID: 23248252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Individualized therapy of disseminated cancer using malignant melanoma as a model.
    Hauschild A; Egberts F; Russo P; Kähler KC
    Cancer Metastasis Rev; 2006 Jun; 25(2):253-6. PubMed ID: 16770537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
    Tran MA; Smith CD; Kester M; Robertson GP
    Clin Cancer Res; 2008 Jun; 14(11):3571-81. PubMed ID: 18519791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
    Broxterman HJ; Georgopapadakou NH
    Drug Resist Updat; 2005 Aug; 8(4):183-97. PubMed ID: 16154800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular-targeted therapies: lessons from years of clinical development.
    Rosa DD; Ismael G; Lago LD; Awada A
    Cancer Treat Rev; 2008 Feb; 34(1):61-80. PubMed ID: 17826917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in targeted therapy for melanoma.
    Friedlander P; Hodi FS
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):619-27. PubMed ID: 21157411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 385.